HSD17B6 delays type 2 diabetes development via inhibiting SREBP activation.

Abstract

BACKGROUND:

The SREBP/SCAP/INSIG complex plays an essential role in SREBP activation and de novo lipogenesis. Whether the activation process is affected by hydroxysteroid 17-beta dehydrogenase 6 (HSD17B6) remains unknown.

METHODS:

SREBP's transcriptional activities were analyzed using an SRE-luciferase (SRE-luc) reporter in 293T cells, Huh7 hepatoma cells, and primary human hepatocytes following a variety of conditions, including ectopic expression of HSD17B6, HSD17B6 mutants defective in its enzymatic activities, knockdown of HSD17B6, and cholesterol starvation. The interaction between HSD17B6 and SREBP/SCAP/INSIG complex was analyzed in 293T cells, Huh7 cells and mouse liver upon ectopic expression of HSD17B6 and its mutants; the interaction was also analyzed using endogenous proteins. The impacts of HSD17B6 on SREBP target expression, glucose tolerance, diet-induced obesity, and type 2 diabetes (T2D) were examined using Huh7 cells in vitro, and with C57BL/6 and NONcNZO10/LtJ T2D mice in vivo.

RESULTS:

HSD17B6 binds to the SREBP/SCAP/INSIG complex and inhibits SREBP signaling in cultured hepatocytes and mouse liver. Although HSD17B6 plays a role in maintaining the equilibrium of 5α-dihydrotestosterone (DHT) in the prostate, a mutant defective in androgen metabolism was as effective as HSD17B6 in inhibiting SREBP signaling. Hepatic expression of both HSD17B6 and the defective mutant improved glucose intolerance and reduced hepatic triglyceride content in diet-induced obese C57BL/6 mice, while hepatic knockdown of HSD17B6 exacerbated glucose intolerance. Consistent with these results, liver-specific expression of HSD17B6 in a polygenic NONcNZO10/LtJ T2D mice reduced T2D development.

CONCLUSIONS:

Our study unveils a novel role of HSD17B6 in inhibiting SREBP maturation via binding to the SREBP/SCAP/INSIG complex; this activity is independent of HSD17B6's sterol oxidase activity. Through this action, HSD17B6 improves glucose tolerance and attenuates the development of obesity-induced T2D. These findings position HSD17B6 as a potential therapeutic target for T2D therapy.

• Authors: Fengxiang Wei, Yan Gu, Lizhi He, Anil Kapoor, Xiaozeng Lin, Ying Dong, Yingying Su, Sandra Vega Neira, Damu Tang
• Journal: Metabolism: clinical and experimental (Metabolism) Vol. 145 Pg. 155631 (08 2023) ISSN: 1532-8600 [Electronic] United States
• PMID: 37330135 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.

Chemical References

• Sterol Regulatory Element Binding Protein 1
• Intracellular Signaling Peptides and Proteins
• Glucose
• HSD17B6 protein, human
• Racemases and Epimerases

Topics

• Male
• Mice
• Humans
• Animals
• Sterol Regulatory Element Binding Protein 1 (metabolism)
• Diabetes Mellitus, Type 2 (genetics)
• Glucose Intolerance
• Intracellular Signaling Peptides and Proteins
• Mice, Inbred C57BL
• Obesity
• Glucose
• Racemases and Epimerases